

# STEADFAST

## An Alzheimer's Research Study

### Aim

To evaluate the safety and tolerability of 5mg of Azeliragon compared to placebo in participants with mild Alzheimer's disease over an 18-month treatment period.

### Protocol

Randomized, double-blind, placebo controlled, multi-centre trial to evaluate the efficacy and safety of Azeliragon in patients with mild Alzheimer's disease receiving a acetylcholinesterase inhibitor.

### Hypothesis

Azeliragon reduces A $\beta$  deposition in the brain and thus may be useful as a disease-modifying agent.

**TGA Trial: NCT02080364**

### Status

Enrolments opened December 2016

### Funding

- vTv Therapeutics
- Neurodegenerative Disorders Research Pty Ltd

### Criteria

To be eligible for the Steadfast Study participants must:

- be 50 years of age or older,
- have a diagnosis of mild Alzheimer's disease,
- have a MMSE score between 21 to 26, and
- be on a stable dose of background therapy for Alzheimer's disease.

### Ethics approval

Bellberry Human Research Ethics Committee  
2016-06-547.

### Contact

Professor Peter K Panegyres, MD PhD FRACP  
Principal Investigator  
Neurodegenerative Disorders Research Pty Ltd  
4 Lawrence Avenue, West Perth WA 6005

Phone: (08) 9481 6293  
Fax: (08) 9481 6294  
Email: [research@ndr.org.au](mailto:research@ndr.org.au)